These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 38426479)

  • 1. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
    Kurai D; Mizukami A; Preckler V; Verelst F; Molnar D; Matsuki T; Ho Y; Igarashi A
    Expert Rev Vaccines; 2024; 23(1):303-311. PubMed ID: 38426479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.
    Ison MG; Papi A; Athan E; Feldman RG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Verheust C; Dezutter N; Gruselle O; Fissette L; David MP; Kostanyan L; Hulstrøm V; Olivier A; Van der Wielen M; Descamps D;
    Clin Infect Dis; 2024 Jun; 78(6):1732-1744. PubMed ID: 38253338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
    Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
    N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
    Feldman RG; Antonelli-Incalzi R; Steenackers K; Lee DG; Papi A; Ison MG; Fissette L; David MP; Maréchal C; Van der Wielen M; Kostanyan L; Hulstrøm V;
    Clin Infect Dis; 2024 Jan; 78(1):202-209. PubMed ID: 37698366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
    Curran D; Matthews S; Cabrera ES; Pérez SN; Breva LP; Rämet M; Helman L; Park DW; Schwarz TF; Melendez IMG; Schaefer A; Roy N; Stephan B; Molnar D; Kostanyan L; Powers JH; Hulstrøm V;
    Influenza Other Respir Viruses; 2024 Feb; 18(2):e13236. PubMed ID: 38314063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States.
    Molnar D; La EM; Verelst F; Poston S; Graham J; Van Bellinghen LA; Curran D
    Infect Dis Ther; 2024 Apr; 13(4):827-844. PubMed ID: 38507143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
    J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
    Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
    Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
    Ferguson M; Schwarz TF; Núñez SA; Rodríguez-García J; Mital M; Zala C; Schmitt B; Toursarkissian N; Mazarro DO; Großkopf J; Voors-Pette C; Mehta H; Hailemariam HA; de Heusch M; Salaun B; Damaso S; David MP; Descamps D; Hill J; Vandermeulen C; Hulstrøm V;
    Clin Infect Dis; 2024 Oct; 79(4):1074-1084. PubMed ID: 39099093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.
    Buynak R; Cannon K; DeAtkine D; Kirby J; Usdan L; Bhavsar A; Gérard C; Kuznetsova A; Jayadev A; Amare H; Valenciano S; Meyer N
    Infect Dis Ther; 2024 Aug; 13(8):1789-1805. PubMed ID: 38981954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model.
    Van Effelterre T; Hens N; White LJ; Gravenstein S; Bastian AR; Buyukkaramikli N; Cheng CY; Hartnett J; Krishnarajah G; Weber K; Pastor LH
    Clin Infect Dis; 2023 Aug; 77(3):480-489. PubMed ID: 36949605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial.
    Clark R; Davies S; Labrador J; Loubet P; Natalini Martínez S; Moríñigo HM; Nicolas JF; Vera MP; Rämet M; Rebollo-Rodrigo MH; Sanz-Muñoz I; Dezutter N; Germain S; David MP; Jayadev A; Amare Hailemariam H; Kotb S; Meyer N
    Clin Infect Dis; 2024 Oct; 79(4):1088-1098. PubMed ID: 39099085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
    Leroux-Roels I; Davis MG; Steenackers K; Essink B; Vandermeulen C; Fogarty C; Andrews CP; Kerwin E; David MP; Fissette L; Vanden Abeele C; Collete D; de Heusch M; Salaun B; De Schrevel N; Koch J; Verheust C; Dezutter N; Struyf F; Mesaros N; Tica J; Hulstrøm V
    J Infect Dis; 2023 Mar; 227(6):761-772. PubMed ID: 35904987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In older adults, an AS01
    Awar M; Mylonakis E
    Ann Intern Med; 2023 Jun; 176(6):JC62. PubMed ID: 37276600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
    Hermida N; Ferguson M; Leroux-Roels I; Pagnussat S; Yaplee D; Hua N; van den Steen P; Anspach B; Dieussaert I; Kim JH
    J Infect Dis; 2024 Aug; 230(2):e353-e362. PubMed ID: 38133639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.